CD8A and neoplasm: Mechanistically, the combination therapy induces unique cellular responses that are not observed with monotherapies, marked by an increase in the frequency of activated, terminally differentiated effector CD8+ T-cells and T helper type 1 (Th1)-like CD4+ effector T-cells, which are crucial for effective anti-tumor responses [43].